Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDXK | O00764 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | WEE1 | P30291 | 1/20 | 0.52 |
| ▸ | NEK3 | P51956 | 1/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.52 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.52 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.52 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.52 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 4/20 | 0.51 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12662354 | 1.00 | PDXK (0.52) | PDXKBRD4WEE1NEK3PLK1 | |
| SCHEMBL736977 | 1.00 | PDXK (0.52) | PDXKBRD4WEE1NEK3PLK1 | |
| SCHEMBL12893295 | 0.96 | PDXK (0.50) | PDXKBRD4WEE1NEK3PLK1 | |
| SCHEMBL13457659 | 0.92 | HTR4 (0.52) | HTR4ACHEMCHR1F10 | |
| SCHEMBL12893438 | 0.90 | HTR4 (0.52) | PDXKBRD4WEE1NEK3PLK1 | |
| SCHEMBL12893778 | 0.90 | HTR4 (0.52) | PDXKBRD4WEE1NEK3PLK1 | |
| SCHEMBL12893418 | 0.90 | HTR4 (0.57) | HTR4ACHEMCHR1 | |
| SCHEMBL13652983 | 0.89 | IGF1R (0.53) | PDXKBRD4WEE1NEK3PLK1 | |
| SCHEMBL18623963 | 0.89 | IGF1R (0.53) | PDXKBRD4WEE1NEK3PLK1 | |
| SCHEMBL13457686 | 0.88 | HTR4 (0.52) | HTR4ACHEMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688685-B2 | Method for preparing volasertib and intermediate thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-06-27 | — | — | US | disclosed |
| US-9688685-B2 | Method for preparing volasertib and intermediate thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-06-27 | — | — | US | disclosed |
| US-20170073350-A1 | Method for Preparing Volasertib and Intermediate thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-03-16 | — | — | US | disclosed |
| US-20170073350-A1 | Method for Preparing Volasertib and Intermediate thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-03-16 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| EP-2610256-B1 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LTD (GB) | 2016-04-27 | — | — | EP | disclosed |
| EP-2610256-B1 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LTD (GB) | 2016-04-27 | — | — | EP | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-7759485-B2 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| EP-2205603-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Cyclacel Limited (GB) | 2010-07-14 | — | — | EP | disclosed |
| WO-2010025073-A1 | DIHYDROIMIDAZO [ 1, 5-F] PTERIDINES AS POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | WO | disclosed |
| WO-2009040556-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009040556-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2009-04-02 | — | — | WO | disclosed |
| US-20090030004-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | ONCOHEROES BIOSCIENCES INC. | 2009-01-29 | — | — | US | disclosed |
| US-7439358-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20070203146-A1 | N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | ONCOHEROES BIOSCIENCES INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203146-A1 | N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | DHPS, PKD1, AQP4 | PDXK 1115/4885BRD4 453/4885WEE1 3301/4885 |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | PDXK 1424/4885BRD4 4869/4885WEE1 4357/4885 |
| US-20170073350-A1 | Method for Preparing Volasertib and Intermediate thereof | CDK8, MDK, WEE1 | PDXK 82/4885BRD4 535/4885WEE1 3/4885 |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | PDXK 37/4885BRD4 1149/4885WEE1 374/4885 |
| US-20090030004-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | QDPR, REN, DHPS | PDXK 728/4885BRD4 645/4885WEE1 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.